Bedke, Jens

Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 3,403

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 1,791

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Powles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., Nosov, D., Pouliot, F., Melichar, B., Vynnychenko, I., et al. (2020) · The Lancet Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 751

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 643

Impact of an Altered Wnt1/β-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma

Kruck, S., Eyrich, C., Scharpf, M., Sievert, K.-D., Fend, F., Stenzl, A., & Bedke, J. (2013) · International Journal of Molecular Sciences

Renal cell carcinoma treatmentWnt/β-catenin signaling in development and cancer

Cited by 70